Drug Discovery and U.S. Expansion Through a Business and Capital Alliance with JCR Pharmaceuticals
First written in FY2018-Q2. 8 of 11 entries say "Advanced", first in FY2018-Q3. Latest entry: FY2026.
No other company in this theme has enough history to compare yet.
- FY2026AdvancedAnnual report
「As part of these initiatives, for JR-446, a treatment for mucopolysaccharidosis type IIIB created by JCR, the U.S. Food and Drug Administration (FDA) granted orphan-drug designation in May 2025, the European Commission (EC) granted orphan medicinal product designation in June of the same year, and the Ministry of Health, Labour and Welfare granted orphan drug designation in September of the same year, marking important milestones. In addition, in August of the same year, JCR entered into a license agreement for commercialization outside Japan and a joint development and commercialization agreement in Japan for JR-479, a drug candidate under development by JCR for GM2 gangliosidosis, a type of lysosomal disease.」
The partnership with JCR progressed to concrete milestones: orphan drug designations for JR-446 in the US, Europe and Japan, and the execution of an overseas license agreement and a co-development agreement in Japan for JR-479. - FY2025AdvancedAnnual report
「As part of this initiative, in December 2024, the first subject received the initial dose in a domestic Phase I/II clinical trial of JR-446, a treatment for mucopolysaccharidosis type IIIB created by JCR Pharmaceuticals Co., Ltd., achieving an important milestone.」
As part of the global expansion of the ultra-rare disease partnership with JCR Pharmaceuticals, the first subject received the initial dose in the domestic Phase I/II clinical trial of JR-446 in December 2024. - FY2024AdvancedAnnual report
「Furthermore, as part of our global efforts to develop new drugs for ultra-rare diseases, in September 2023 we entered into a license agreement for the overseas commercialization of a treatment for mucopolysaccharidosis type IIIB, a lysosomal disease, being developed by JCR Pharmaceuticals Co., Ltd. (Ashiya, Hyogo; "JCR"), and a co-development and commercialization agreement for Japan.」
The partnership with JCR progressed from negotiations on the commercialization of four compounds for ultra-rare diseases to the execution of an overseas license agreement and a co-development and commercialization agreement in Japan for JR-446. - FY2023-Q3AdvancedAnnual report
「In October 2022, we entered into a memorandum of understanding (the "MOU") with JCR Pharmaceuticals Co., Ltd. (Ashiya, Hyogo; "JCR") concerning the grant of exclusive negotiating rights for the commercialization, worldwide excluding Japan, of four drug candidate compounds (the "Compounds") being developed by JCR for ultra-rare diseases among lysosomal diseases. Based on the MOU, the two companies also entered into a license agreement for the Compound targeting fucosidosis.」
The partnership with JCR Pharmaceuticals progressed to discussions on the commercialization of four drug candidates for ultra-rare diseases worldwide excluding Japan, and the companies also entered into a license agreement for the compound targeting fucosidosis. - FY2022-Q1AdvancedAnnual report
「As part of this initiative, in May 2021, SPLiNE Co., Ltd. (Chuo-ku, Tokyo), a wholly owned consolidated subsidiary of the Company, was entrusted with distribution services for IZCARGO® 10 mg intravenous infusion, a recombinant treatment for mucopolysaccharidosis type II for which JCR Pharmaceuticals Co., Ltd. (Ashiya, Hyogo) obtained marketing approval in March of the same year.」
As part of the post-establishment development of the US joint venture under the partnership with JCR Pharmaceuticals, SPLiNE undertook distribution operations for JCR's new drug Izcargo. - FY2021RestatedAnnual report
「JCR Pharmaceuticals Co., Ltd. | Ashiya, Hyogo | 9,061 | Manufacture and sale of prescription drugs and related products | 23.5 | Business alliance | Interlocking directors」
The company continues its capital and business alliance with JCR Pharmaceuticals and its relationship with the company as an equity-method affiliate. - FY2018RestatedAnnual report
「In September 2017, the company entered into a capital and business alliance with JCR Pharmaceuticals Co., Ltd. (Ashiya, Hyogo; hereinafter, JCR) and acquired 22% of its total issued shares. In January 2018, the company established a joint venture in the United States to develop treatments using JCR's proprietary technology.」
The company reiterated that it had acquired a 22% stake in JCR Pharmaceuticals and established a U.S. joint venture to develop treatments using its proprietary technology. - FY2018-Q3AdvancedAnnual report
「As part of these initiatives, in September 2017 we entered into a capital and business alliance with JCRファーマ株式会社. In January 2018, we established a joint venture in the United States to develop therapeutic drugs using the company’s proprietary technology.」
In January 2018, the company established a joint venture for the development of treatments in the United States under its capital and business alliance with JCR Pharmaceuticals. - FY2018-Q2First statedAnnual report
「As part of these initiatives, in September 2017 we entered into a capital and business alliance with JCRファーマ株式会社 (Ashiya, Hyogo). We are preparing to establish a joint venture in the United States to develop therapeutic drugs using the company’s proprietary technology. We also acquired 22% of the company’s total issued shares.」
The company began a capital and business alliance with JCR Pharmaceuticals and is preparing to establish a joint venture for the U.S. development of treatments using proprietary technology. In its disclosure of material subsequent events, the company also stated that it acquired shares on 31 October 2017, raising its ownership ratio to 22.46% and making JCR Pharmaceuticals an equity-method affiliate.